ArticleThe Journal of clinical investigation1986
Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin.
Article in The Journal of clinical investigation, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 101 citations in OpenAlex.
- Cis-vaccenic acid induces differentiation and up-regulates gamma globin synthesis in K562, JK1 and transgenic mice erythroid progenitor stem cells.European journal of pharmacology · 2016Article
- Influence of IL-3 functional fragment on cord blood stem cell ex vivo expansion and differentiation.Stem cell investigation · 2016Article
- Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro.Japanese journal of cancer research : Gann · 1998Article
- Subcutaneous recombinant erythropoietin in preterminal renal insufficiency.European journal of pediatrics · 1994Article
- Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.The Journal of clinical investigation · 1991Article
- The Jeremiah Metzger lecture. Regulation of hematopoiesis.Transactions of the American Clinical and Climatological Association · 1990Review
- Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.Blut · 1989Review
- Purification of erythroid progenitor cells and characterization of erythropoietin receptors.The British journal of cancer. Supplement · 1988Article
- Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro.Klinische Wochenschrift · 1988Article
- Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3.The Journal of clinical investigation · 1987Article
- Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.The Journal of clinical investigation · 1987Article
- Hematopoietic growth factors.The Journal of clinical investigation · 1987Article
- Interleukin 1 induces cultured human endothelial cell production of granulocyte-macrophage colony-stimulating factor.The Journal of clinical investigation · 1987Article
- Characterization of hematopoietic stem and progenitor cells.Immunologic research · 1987Review
- Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level.The Journal of clinical investigation · 1986Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human bone marrow cells were sequentially fractionated by three negative selection steps to remove adherent cells and Fc receptor-bearing cells, followed by immune adsorption (panning) to deplete maturing cells that react with a panel of monoclonal antibodies. This nonadherent Fc receptor and antibody negative fraction could be further enriched by a positive selection "panning" step, using an antibody to HLA-DR antigen; 12-27% of the cells formed erythroid burst-forming unit (BFU-E), erythroid colony-forming unit, granulocyte-monocyte colony-forming unit, and erythroid and granulocyte and/or monocyte colony-forming unit-derived colonies with recovery of 0.5-1% of the cells and 20-100% of the colony-forming cells. Sequential fractionation resulted in increasing dependence of a subset of BFU-E-derived colonies on exogenous burst-promoting activity (BPA) for proliferation in culture, but the most enriched progenitor fraction still contained a proportion of accessory cell or BPA-independent BFU-E that responded to either natural or biosynthetic erythropoietin when added to cultures on day 0 in the absence of BPA. If the addition of erythropoietin was delayed until day 3, the data suggest that this population of BFU-E either died or became unresponsive to erythropoietin. Delayed addition of erythropoietin to cultures of enriched progenitors provided a sensitive BPA assay, since BPA-independent but erythropoietin-responsive BFU-E were eliminated. The surviving BFU-E that were dependent for their proliferation on the presence of both BPA and erythropoietin showed a characteristic dose response to increasing BPA concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.